These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Antibacterial carbonic anhydrase inhibitors: an update on the recent literature. Supuran CT; Capasso C Expert Opin Ther Pat; 2020 Dec; 30(12):963-982. PubMed ID: 32806966 [TBL] [Abstract][Full Text] [Related]
14. Carbonic anhydrase inhibitors and activators for novel therapeutic applications. Supuran CT Future Med Chem; 2011 Jul; 3(9):1165-80. PubMed ID: 21806379 [TBL] [Abstract][Full Text] [Related]
15. Carbonic anhydrase inhibitors: a review on the progress of patent literature (2011-2016). Lomelino C; McKenna R Expert Opin Ther Pat; 2016 Aug; 26(8):947-56. PubMed ID: 27387065 [TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas. Supuran CT Expert Opin Ther Pat; 2018 Oct; 28(10):709-712. PubMed ID: 30217119 [No Abstract] [Full Text] [Related]
18. Inhibition of Bacterial Carbonic Anhydrases as a Novel Approach to Escape Drug Resistance. Capasso C; Supuran CT Curr Top Med Chem; 2017; 17(11):1237-1248. PubMed ID: 28049405 [TBL] [Abstract][Full Text] [Related]
19. The η-class carbonic anhydrases as drug targets for antimalarial agents. Supuran CT; Capasso C Expert Opin Ther Targets; 2015 Apr; 19(4):551-63. PubMed ID: 25495426 [TBL] [Abstract][Full Text] [Related]
20. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Supuran CT Nat Rev Drug Discov; 2008 Feb; 7(2):168-81. PubMed ID: 18167490 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]